Displaying drugs 10651 - 10675 of 12591 in total
Vamifeport
Vamifeport is being investigated for the treatment of beta-thalassemia.
Investigational
Matched Description: … Vamifeport is being investigated for the treatment of beta-thalassemia. …
TZ-101
TZ-101 composes of GDP-L-fucose and fucosyltransferase VI
Investigational
Matched Description: … TZ-101 composes of [GDP-L-fucose] and fucosyltransferase VI …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... The combination of selectivity for the beta form of the receptor, liver targeting and other structural ... is designed to provide significant efficacy while avoiding side effects associated with activation of …
Tunicamycin
Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes. One member of this family is the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of glycoprotein synthesis in eukaryotes. Tunicamycin blocks...
Experimental
Matched Description: … HexNAc-1-P family of enzymes. ... of glycoprotein synthesis in eukaryotes. ... Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P …
Tipifarnib
Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia (AML) and other types of cancer. It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Investigational
Matched Description: … (AML) and other types of cancer. ... It belongs to the family of drugs called farnesyltransferase inhibitors. ... Tipifarnib (R-115777) is a substance that is being studied in the treatment of acute myeloid leukemia …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … , thereby addressing one of the major challenges in treating schizophrenia today. ... ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA ... It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition …
Odronextamab
Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma (NHL).[A254187,A254197] Preliminary studies have shown that in patients with R/R NHL, the use of odronextamab does not lead to the development of neurologic toxicity; however, it can...
Investigational
Matched Description: … does not lead to the development of neurologic toxicity; however, it can lead to the development of ... cytokine release syndrome (CRS), a serious condition associated with the use of immunotherapy. ... human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of …
KIN-3248
KIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and 20-35% of urothelial cancers, respectively. While effective, disease progression may occur 6 to 8 months...
Investigational
Matched Description: … Therefore, the broad inhibition of FGFR isoforms may be effective against different types of tumors. ... cholangiocarcinoma and 20-35% of urothelial cancers, respectively. ... was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of …
Tesevatinib
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs,...
Investigational
Matched Description: … Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer ... demonstrated potent inhibition of tumor growth and causes tumor regression. ... Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases …
αAβ–Gas6
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody ... [A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the ... fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand …
BBV152
BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). The candidate, a whole virion inactivated SARS-CoV-2 vaccine, was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of either aluminum hydroxide gel (Algel) or a novel TLR7/8 agonist adsorbed gel....
Investigational
Matched Description: … The components of the vaccine include BBV152A, BBV152B, and BBV152C. ... BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR). ... , was developed from a well-known SARS-CoV-2 strain and a vero cell platform (CCL-81) with adjuncts of …
PA-1050040
PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Investigational
Matched Description: … It inhibits virus replication by the same mechanism of action as BVM. ... PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). …
Paltusotine
Paltusotine is under investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)).
Investigational
Matched Description: … Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)). ... investigation in clinical trial NCT04261712 (A Study to Evaluate the Long-term Safety and Efficacy of …
Oxelumab
Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma).
Investigational
Matched Description: … of Allergen-induced Airway Obstruction in Adults With Mild Allergic Asthma). ... Oxelumab is under investigation in clinical trial NCT00983658 (A Study of HuMAb OX40L in the Prevention …
HPV-16 trojan peptide vaccine
HPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific CD4 and CD8 T cell responses.
Investigational
Matched Description: … HPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan ... peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific …
IDM-1
IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific anti-HER-2/neu antibody developed by Medarex Inc.
Investigational
Matched Description: … IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer. ... It is comprised of MAK(Monocytes-derived Activated Killer) cells associated with MDX-210, a bispecific …
CERE-110
CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes through an adeno-associated viral vector (AAV) delivery system. This drug is developed by Ceregene and currently under phase I of clinical trial.
Investigational
Matched Description: … This drug is developed by Ceregene and currently under phase I of clinical trial. ... CERE-110 is a gene-therapy product that involves in vivo delivery of nerve growth factor (NGF) genes …
Nitenpyram
Nitenpyram is an insecticide used in agriculture and veterinary medicine to kill external parasites of pets. It is a neonicotinoid, a neurotoxin that blocks neural messages and binds particularly tightly in the central nervous system of insects, causing rapid death.
Experimental
Vet approved
Matched Description: … Nitenpyram is an insecticide used in agriculture and veterinary medicine to kill external parasites of ... neurotoxin that blocks neural messages and binds particularly tightly in the central nervous system of …
Pentaglobin
Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched by immunoglobulin M (IgM).
Investigational
Matched Description: … Pentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin ... [A220173] It is comprised of [immunoglobulin G (IgG)](https://www.drugbank.ca/drugs/DB00028) and immunoglobulin …
SB 11285
SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors).
Investigational
Matched Description: … SB 11285 is a second-generation Stimulator of Interferon Genes (STING) agonist. ... L45123] SB 11285 is under investigation in clinical trial NCT04096638 (Evaluating Safety and Efficacy of …
Tralesinidase alfa
Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2. It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.
Investigational
Matched Description: … Tralesinidase alfa is a chimeric fusion protein comprised of recombinant human NAGLU and a modified human ... It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known …
SIG-007
SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.
Investigational
Matched Description: … Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease. ... SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector …
OTL-102
OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene. It is being investigated for the treatment of X-linked chronic granulomatous disease.
Investigational
Matched Description: … It is being investigated for the treatment of X-linked chronic granulomatous disease. ... OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells …
CDP323
CDP323 is an antagonist of the vascular cell adhesion molecule 1 (VCAM-1) binding to alpha4-integrins (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis (MS). It is considered a small-molecule prodrug. CDP323 was originally developed by the British biopharmaceutical company Celltech plc. (now UCB...
Investigational
Matched Description: … (now UCB S.A.) and is a putative new drug for oral treatment of multiple sclerosis. ... CDP323 is an antagonist of the _vascular cell adhesion molecule 1_ (VCAM-1) binding to alpha4-integrins ... (other adhesion molecules), a process thought to be implicated in the pathophysiology of Multiple Sclerosis …
Orgotein
Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage. Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide radical into either the less damaging hydrogen peroxide or molecular oxygen. Hydrogen peroxide can be degraded by catalase. The antioxidant...
Investigational
Vet approved
Matched Description: … The antioxidant mechanism of SOD is common to most organisms exposed to oxygen. ... Superoxide is a natural byproduct of oxygen metabolism which, if left unchecked, leads to cell damage ... Superoxide dismutase (SOD) is an enzyme that alternately catalyzes the dismutation of the superoxide …
Displaying drugs 10651 - 10675 of 12591 in total